Breakthrough Discoveries for Thriving with Bipolar Disorder

BD2: A Longitudinal Cohort Study

In 2023, the Heinz C. Prechter Bipolar Research Program was named as one of six institutions that is part of the BD² Integrated Network with BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder. Along with Brigham and Women’s Hospital-McLean Hospital, University of California Los Angeles, Johns Hopkins University, Mayo Clinic, UTHealth Houston, the Prechter Program at the University of Michigan will work in partnership with clinicians, researchers, and lived experience individuals to expand knowledge of bipolar disorder while accelerating the translation of that knowledge into clinical care. Over the next five years, the BD² Integrated Network will engage 4,000 people living with bipolar disorder as part of a longitudinal cohort study.

The Prechter Program is seeking people who have a diagnosis of bipolar I disorder to participate in a research study. The purpose of this study is to create a database of information that allows researchers to explore how genetics and other biomarkers are impacted by bipolar disorder and its treatment. This information will be useful in learning more about bipolar disorder and to assist in the development of individualized care.

You may be eligible to participate if:

  • You are 18-75 years of age
  • You have been diagnosed with bipolar I disorder

If you choose to participate in the study, you will be asked to complete four annual in-person study visits—consisting of cognitive assessments, blood draw, and an MRI scan—as well as to complete a series of short online surveys periodically over the course of four years. Compensation will be provided for your time.

For more information, please contact a member of our study team:

Christine Ribbens Grimm, B.A., B.S.N., R.N.
Study Coordinator

The Prechter Program BD2 Study Team